Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1

Immunological Reviews

Volumn 237, Issue 1, 2010, Pages 226-248

  Graham, John P ^a   Arcipowski, Kelly M ^a   Bishop, Gail A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

B lymphocyte; CD40; LMP1; lymphocyte activation; signal transduction

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE; CYTOKINE; LATENT MEMBRANE PROTEIN 1;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; AUTOIMMUNITY; B CELL LYMPHOMA; B LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

ANTIGENS, CD40; B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; MOLECULAR MIMICRY; NEOPLASMS; SIGNAL TRANSDUCTION; VIRAL MATRIX PROTEINS;

EID: 77955903717     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00932.x     Document Type: Review

References (239)

1. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009 11:247.
2. Bishop GA, Hostager BS. The CD40-CD154 interaction in B cell-T cell liaisons. Cyt & Growth Factor Rev 2003 14:297 309.
3. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40CD40L engagement in the immune system. Immunol Rev 2009 229:152 172.
4. Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001 24:97 109.
5. Bishop GA, Busch LK. Molecular mechanisms of B lymphocyte transformation by Epstein-Barr virus. Microbes Infec 2002 4:853 857.
6. Lam N, Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 2003 15:9 16.
7. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. Comparative Analysis of signal Transduction by CD40 and the EBV oncoprotein LMP1 in vivo. J Virol 2004 78:13253 13261.
8. Wang D, Liebowitz DN, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985 43:831 840.
9. Kaye KM, Izumi KM, Kieff E. EBV LMP1 is essential for B-lymphocyte growth transformation: EBV strategy in normal and neoplastic B cells. Proc Natl Acad Sci USA 1993 90:9150 9154.
10. Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Sem Cancer Biol 2008 18:388 396.
11. Braesch-Andersen S, Paulie S, Koho H, Nika H, Aspenstrom P, Perlmann P. Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J Immunol 1989 142:562 567.
12. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40CD40L signaling and its implication in health and disease. BioFactors 2009 35:474 483.
13. Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 1985 20:23 28.
14. Ohkawara Y, et al. CD40 expression by human peripheral blood eosinophils. J Clin Invest 1996 97:1761 1766.
15. Tan J, et al. CD40 is expressed and functional on neuronal cells. EMBO J 2002 21:643 652.
16. Schonbeck U, Libby P. The CD40CD154 receptorligand dyad. Cell Mol Life Sci 2001 58:4 43.
17. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP. CD40 expression by human fibroblasts. Clin Immunol Immunopathol 1995 77:42 51.
18. Denfeld RW, et al. CD40 is functionally expressed on human keratinocytes. Eur J Immunol 1996 26:2329 2334.
19. Inwald DP, McDowall AM, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003 92:1041 1048.
20. Armitage RJ, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992 357:80 82.
21. Hollenbaugh D, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992 11:4313 4321.
22. Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D. Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activaiton of B lymphocytes. Eur J Immunol 1992 22:2573 2578.
23. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992 89:6550 6554.
24. Gauchat J-F, et al. CD40L is functionally expressed on human eosinophils. Eur J Immunol 1995 25:863 865.
25. Carbone E, et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40L interaction. J Exp Med 1997 185:2053 2060.
26. Henn V, et al. CD40L on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998 391:591 594.
27. Mach F, et al. Functional CD40L is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40L signaling in atherosclerosis. Proc Natl Acad Sci USA 1997 94:1931 1936.
28. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, Clark EA. Functional CD40L expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 1996 157:4363 4370.
29. Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Sem Immunol 2009 21:257 264.
30. Ma DY, Clark EA. The role of CD40 and CD154CD40L in DC. Sem Immunol 2009 21:265 272.
31. Munroe ME. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Sem Immunol 2009 21:283 288.
32. Dugger K, Lowder TW, Tucker TA, Schwiebert LM. Epithelial cells as immune effector cells: the role of CD40. Sem Immunol 2009 21:289 292.
33. Engel D, et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Sem Immunol 2009 21:308 312.
34. Allen RC, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993 259:990 993.
35. Aruffo A, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993 72:291 300.
36. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993 361:541 543.
37. Kawabe T, et al. The immune responses in CD40-deficient mice: impaired Ig class switching and germinal center formation. Immunity 1994 1:167 178.
38. Xu J, et al. Mice deficient for the CD40 ligand. Immunity 1994 1:423 431.
39. Spriggs MK, et al. Recombinant human CD40 ligand stimulates B cell proliferation and IgE secretion. J Exp Med 1992 176:1543 1550.
40. Banchereau J, De Paoli P, Valle A, Garcia E, Rousset F. Long-term human B cell lines dependent on IL-4 and antibody to CD40. Science 1991 251:70 72.
41. Maliszewski CR, Grabstein K, Fanslow WC, Armitage R, Spriggs MK, Sato TA. Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines. Eur J Immunol 1993 23:1044 1049.
42. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Biol Med 2007 597:131 151.
43. Jabara HH, Weng Y, Sannikova TY, Geha RS. TRAF2 and TRAF3 independently mediate Ig class switching driven by CD40. Int Immunol 2009 21:477 488.
44. Baccam M, Woo S, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kB, AP-1, and CEBP. J Immunol 2003 170:3099 3108.
45. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995 378:617 620.
46. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J Exp Med 1994 180:157 163.
47. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39. J Exp Med 1993 178:1567 1575. (Pubitemid 23318435)
48. Reichmann G, et al. The CD40CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect Immun 2000 68:1312 1318.
49. Chamekh M. CD40-CD40L Interaction in immunity against protozoan infections. J Biomed Biotechnol 2007 2007:59430.
50. Soong L, et al. Disruption of CD40-CD40L interactions results in an enhanced susceptibility to Leishmania amazonesis infection. Immunity 1996 4:263 273.
51. Chen L, et al. Distinct roles of CD28- and CD40 ligand-mediated costimulation in the development of protective immunity and pathology during Chlamydia muridarum urogenital infection in mice. Infect Immun 2009 77:3080 3089.
52. Sitati E, McCandless EE, Klein RS, Diamond MS. CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol 2007 81:9801 9811.
53. van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995 378:620 623.
54. Grabstein KH, et al. The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2. J Immunol 1993 150:3141 3147.
55. Bishop GA, Warren WD, Berton MT. Signaling via MHC class II molecules and antigen receptors enhances the B cell response to gp39CD40 ligand. Eur J Immunol 1995 25:1230 1238.
56. Gascan H, Gauchat JF, Aversa G, Van Vlasselaer P, de Vries JE. Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol 1991 147:8 13.
57. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. IL-10 and TGFB cooperate to induce anti-CD40-activated naive human B cells to secrete IgA. J Exp Med 1992 175:671 682.
58. Snapper CM, Marcu KB, Zelazowski P. The Ig class switch: beyond "accessibility". Immunity 1997 6:217 223.
59. Jabara HH, Geha RS. JNK is essential for CD40-mediated IgE class switching in B cells. J Allergy Clin Immunol 2005 115:856 863.
60. Jumper MD, Splawski JB, Lipsky PE, Meek K. Ligation of CD40 induces sterile transcripts of multiple Ig H chain isotypes in human B cells. J Immunol 1994 152:438 445.
61. Warren WD, Berton MT. Induction of germ-line 1 and Ig gene expression in murine B cells. IL-4 and the CD40L-CD40 interaction provide distinct but synergistic signals. J Immunol 1995 155:5637 5646.
62. Iciek LA, Delphin SA, Stavnezer J. CD40 cross-linking induces Ig germline transcripts in B cells via activation of NF-kB. Synergy with IL-4 induction. J Immunol 1997 158:4769 4779.
63. Jabara HH, et al. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated Ig class switching. Immunity 2002 17:265 276.
64. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol 2008 26:261 292.
65. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai S, Honjo T. CSR and hypermutation require AID, a potential RNA editing enzyme. Cell 2000 102:553 564.
66. Dedeoglu F, Horwitz B, Chaudhuri J, Alt FW, Geha RS. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFkB. Int Immunol 2004 16:395 404.
67. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989 342:929 931.
68. Benson RA, Hostager BS, Bishop GA. Rapid CD40-mediated rescue from CD95-induced apoptosis requires TRAF6 and PI3K. Eur J Immunol 2006 36:2535 2543.
69. Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 2009 9:15 27.
70. Yang Y, Wilson JM. CD40L-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 1996 273:1862 1864.
71. Pai SaK R. Role of LMP1 in immune control of EBV infection. Sem Cancer Biol 2001 11:455 460.
72. Thorley-Lawson DA. EBV: exploiting the immune system. Nat Rev Immunol 2001 1:75 82.
73. Küppers R. B cells under influence: transformation of B cells by EBV. Nat Rev Immunol 2003 3:801 812.
74. Lu J, et al. Epstein-Barr virus facilitates the malignant potential of immortilzed epithelial cells: from latent genome to viral production and maintenance. Lab Invest 2009 90:1 14.
75. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004 10:803 821.
76. Young LS, Rickinson AB. Epstein-Barr Virus: 40 Years On. Nat Rev Cancer 2004 4:757 768.
77. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Sem Cancer Biol 2001 11:435 444.
78. Rastelli J, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood 2008 111:1448 1455.
79. Halder S, Murakami M, Verma SC, Kumar P, Yi F, Robertson ES. Early events associated with infection of EBV infection of primary B-cells. PLoS ONE 2009 4:1 16.
80. Guerreiro-Cacais AO, et al. Capacity of EBV to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J Gen Virol 2004 85:2767 2778.
81. Savard M, Gosselin J. EBV immunosuppression of innate immunity mediated by phagocytes. Virus Res 2006 119:134 135.
82. Tugizov S, Herrera R, Veluppilai P, Greenspan J, Greenspan D, Palefsky JM. EBV-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium. J Virol 2007 81:5484 5496.
83. Eliopoulos AG, Rickinson AB. LMP1 masquerades as an active receptor. Curr Biol 1998 8:R196 R198.
84. Ahsan N, Kanda T, Kazuo N, Takada K. EBV transforming protein LMP1 plays a critical role in virus production. J Virol 2005 79:4415 4424.
85. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998 9:395 404.
86. Shannon-Lowe C, Adland E, Bell AI, Delecluse H, Rickinson AB, Rowe M. Features distinguishing EBV infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol 2009 83:7749 7760.
87. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004 350:1328 1337.
88. Fennewald S, van Santen V, Kieff E. Nucleotide Sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 1984 51:411 419.
89. Kilger E, Kieser A, Baumann M, Hammerschmidt W. EBV-mediated B cell proliferation is dependent upon LMP1, which simulates an activated CD40 receptor. EMBO J 1998 17:1700 1709.
90. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. Expression of the EBV LMP1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998 95:11963 11968.
91. Uchida J, et al. Mimicry of CD40 signals by EBV LMP1 in B lymphocyte responses. Science 1999 286:300 303.
92. Stunz LL, et al. Expression of the LMP1 cytoplasmic tail in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 2004 21:255 266.
93. Morris MA, Dawson CW, Young LS. Role of the EBV-encoded LMP1 in the pathogenesis of NPC. Fut Oncology 2009 5:811 825.
94. Loskog ASI, Eliopoulos AG. The Janus faces of CD40 in cancer. Sem Immunol 2009 21:301 307.
95. Grassmé H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J Immunol 2002 168:298 307.
96. Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40, TRAF2 and TRAF3 to membrane microdomains during CD40 signaling. J Biol Chem 2000 275:15392 15398.
97. Busch LK, Bishop GA. The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocytes. J Immunol 1999 162:2555 2561.
98. Aviel S, Winberg G, Massucci M, Ciechanover A. Degradation of the EBV latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J Biol Chem 2000 275:23491 23499. (Pubitemid 30624630)
99. Busch LK, Bishop GA. Multiple carboxyl-terminal regions of the EBV oncoprotein, LMP1, cooperatively regulate signaling to B lymphocytes via TRAF-dependent and TRAF-independent mechanisms. J Immunol 2001 167:5805 5813.
100. Brown KD, Hostager BS, Bishop GA. Differential signaling and TRAF degradation by CD40 and the EBV oncoprotein LMP1. J Exp Med 2001 193:943 954.
101. Wajant H, Henkler F, Scheurich P. The TRAF family: scaffold molecules for cytokine receptors, kinases, and their regulators. Cell Signal 2001 13:389 400.
102. Bishop GA. The multifaceted roles of TRAFs in the regulation of B cell function. Nat Rev Immunol 2004 4:775 786.
103. Kraus ZJ, Nakano H, Bishop GA. TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40. Proc Natl Acad Sci USA 2009 106:17140 17145.
104. Pullen SS, Miller HG, Everdeen DS, Dang TTA, Crute JJ, Kehry MR. CD40-TRAF interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochem 1998 37:11836 11845.
105. Lu L, Cook WJ, Lin L, Noelle RJ. CD40 signaling through a newly identified TRAF2 binding site. J Biol Chem 2003 278:45414 45418.
106. Devernge O, et al. Association of TRAF1, TRAF2, and TRAF3 with an EBV LMP1 domain important for B-lymphocyte transformation: role in NF-kB activation. Mol Cell Biol 1996 16:7098 7108.
107. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP1 association with TRAF1, 2 and 3. J Virol 1997 71:4649 4656.
108. Schultheiss U, et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene LMP1. EMBO J 2001 20:5678 5691.
109. Kaye KM, Izumi KM, Mosialos G, Kieff E. The EBV LMP1 cytoplasmic C-terminus is essential for B lymphocyte transformation; fibroblast cocultivation complements a critical funtion within the terminal 155 residues. J Virol 1995 69:675 683.
110. Izumi KM, Kaye KM, Kieff ED. The EBV LMP1 amino acid sequence that engages TRAFs is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 1997 94:1447 1452.
111. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The EBV LMP1 mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995 4:549 560.
112. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. Localization of the major NF-kB activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 1997 272:19777 19784.
113. Floettmann JE, Eliopoulos AG, Jones M, Young LS, Rowe M. EBV LMP1 signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene 1998 17:2383 2392.
114. Xie P, Bishop GA. Roles of TRAF3 in signaling to B lymphocytes by CTAR regions 1 and 2 of the EBV-encoded oncoprotein LMP1. J Immunol 2004 173:5546 5555.
115. Wu L, Nakano H, Wu Z. The CTAR2 of the EBV-encoded LMP1 activates NF-kB through TRAF6 and TAK1. J Biol Chem 2006 281:2162 2169.
116. Rowland SR, Tremblay ML, Ellison JM, Stunz LL, Bishop GA, Hostager BS. A novel mechanism for TRAF6-dependent CD40 signaling. J Immunol 2007 179:4645 4653.
117. Ren CL, Morio T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase Cg2. J Exp Med 1994 179:673 680.
118. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-kB. J Immunol 1994 153:4357 4366.
119. Sakata N, Patel HR, Terada N, Aruffo A, Johnson GL, Gelfand E. Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. J Biol Chem 1995 270:30823 30828.
120. Li Y-Y, Baccam M, Waters SB, Pessin JE, Bishop GA, Koretzky GA. CD40 ligation results in PKC-independent activation of ERK and JNK in resting murine splenic B cells. J Immunol 1996 157:1440 1447.
121. Roberts ML, Cooper NR. Activation of a Ras-MAPK-dependent pathway by EBV LMP1 is essential for cellular transformation. Virol 1998 240:93 99.
122. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998 16:1731 1742.
123. Coope HJ, et al. CD40 regulates the processing of NF-kB2 p100 to p52. EMBO J 2002 21:5375 5385.
124. Luftig M, et al. EBV LMP1 TRAF-binding site induces NIKIKKa-dependent noncanonical NF-kB activation. Proc Natl Acad Sci USA 2004 101:141 146.
125. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA. Cooperation between TRAFs 1 and 2 in CD40 signaling. J Immunol 2006 176:5388 5400.
126. Hu HM, O'Rourke K, Boguski MS, Dixit VM. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994 269:30069 30072.
127. Cheng G, Cleary AM, Ye Z, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995 267:1494 1498.
128. Kuhné MR, et al. Assembly and regulation of the CD40 receptor complex in human B cells. J Exp Med 1997 186:337 342.
129. Ishida T, et al. TRAF5, a novel TNF-R-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996 93:9437 9442.
130. Lomaga MA, et al. TRAF6 deficiency results in osteopetrosis and defective IL-1, CD40, and LPS signaling. Genes Dev 1999 13:1015 10121.
131. Jalukar SV, Hostager BS, Bishop GA. Characterization of the roles of TRAF6 in CD40-mediated B lymphocyte effector functions. J Immunol 2000 164:623 630.
132. Hsing Y, Hostager BS, Bishop GA. Characterization of CD40 signaling determinants regulating NF-kB activation in lymphocytes. J Immunol 1997 159:4898 4906.
133. Sutherland CL, Krebs DL, Gold MR. An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of JNK, activation of MAPKAP kinase-2, phosphorylation of IkBa, and protection of WEHI-231 cells from anti-IgM-induced growth arrest. J Immunol 1999 162:4720 4730.
134. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kB by TNF receptor 2 and CD40. Science 1995 269:1424 1427.
135. Hostager BS, Bishop GA. Cutting edge: contrasting roles of TRAF2 and TRAF3 in CD40-mediated B lymphocyte activation. J Immunol 1999 162:6307 6311.
136. Hostager BS, Haxhinasto SA, Rowland SR, Bishop GA. TRAF2-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003 278:45382 45390.
137. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kB activation in mature B cells. Immunity 2004 21:629 642.
138. Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1, but not CD40, in B lymphocytes. J Exp Med 2004 199:661 671.
139. Guasparri I, Bubman D, Cesarman E. EBV LMP2A affects LMP1-mediated NF-kB signaling and survival of lymphoma cells by regulating TRAF2 expression. Blood 2008 111:3813 3820.
140. Hostager BS, Bishop GA. Role of TRAF2 in the activation of IgM secretion by CD40 and CD120b. J Immunol 2002 168:3318 3322.
141. Haxhinasto SA, Bishop GA. A novel interaction between PKD and TRAFs regulates BCR-CD40 synergy. J Immunol 2003 171:4655 4662.
142. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998 72:7900 7908.
143. Graham JP, Moore CR, Bishop GA. Roles of the TRAF23 binding site in differential B cell signaling by CD40 and its oncogenic mimic, LMP1. J Immunol 2009 183:2966 2973.
144. Wu S, et al. LMP1 protein from EBV is a structural decoy in B lymphocytes for binding to TRAF3. J Biol Chem 2005 280:33620 33626.
145. Chaudhuri A, Orme S, Eilam S, Cherayil BJ. CD40-mediated signals inhibit the binding of TRAF2 to the CD40 cytoplasmic domain. J Immunol 1997 159:4244 4251.
146. Moore CR, Bishop GA. Differential regulation of CD40-mediated TRAF degradation in B lymphocytes. J Immunol 2005 175:3780 3789.
147. Matsuzawa A, et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 2008 321:663 668.
148. Brown KD, Hostager BS, Bishop GA. Regulation of TRAF2 signaling by self-induced degradation. J Biol Chem 2002 277:19433 19438.
149. Nakano H, et al. Targeted disruption of Traf5 gene causes defects in CD40 and CD27-mediated lymphocyte activation. Proc Natl Acad Sci USA 1999 96:9803 9808.
150. Ahonen CL, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol 2002 3:451 456.
151. Haxhinasto SA, Hostager BS, Bishop GA. Cutting Edge: molecular mechanisms of synergy between CD40 and the BCR: role for TRAF2 in receptor interaction. J Immunol 2002 169:1145 1149.
152. Baccam M, Bishop GA. Membrane-bound CD154, but not anti-CD40 mAbs, induces NF-kB independent B cell IL-6 production. Eur J Immunol 1999 29:3855 3866.
153. Lu L-F, et al. The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation. Blood 2007 110:193 200.
154. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997 6:379 388.
155. Revy P, et al. Activation of the Jak3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. J Immunol 1999 163:787 793.
156. Higuchi M, Kieff E, Izumi KM. The EBV LMP1 putative JAK3 binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J Virol 2002 76:455 459.
157. Garceau N, et al. Lineage-restriced function of NIK in transducing signals via CD40. J Exp Med 2000 191:381 385.
158. Yin L, et al. Defective LT- receptor-induced NF-kB transcriptional activity in NIK-deficient mice. Science 2001 291:2162 2165.
159. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and canonical NF-kB activation pathways by NIK. Immunity 2004 21:477 489.
160. Kosaka Y, et al. Activation and regulation of the IkB kinase in human B cells by CD40 signaling. Eur J Immunol 1999 29:1353 1362.
161. Qian Y, et al. Act1, a negative regulator in CD40 and BAFF-mediated B cell survival. Immunity 2004 21:575 587.
162. Claudio E, et al. The adaptor protein CIKSAct1 is essential for IL-25-mediated allergic airway inflammation. J Immunol 2009 182:1617 1630.
163. Aiba Y, et al. BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 2006 24:259 268.
164. Qiao G, et al. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Cbl-b. J Immunol 2007 179:4473 4479.
165. Salmon RA, Foltz IN, Young PR, Schrader JW. The p38 MAPK is activated by ligation of the T or B lymphocyte antigen receptors, Fas, or CD40, but suppression of kinase activity does not inhibit apoptosis induced by antigen receptors. J Immunol 1997 159:5309 5317.
166. Eliopoulos AG, Wang C-C, Dumitru CD, Tsichilis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulate IgE induction by CD40. EMBO J 2003 22:3855 3864.
167. Papoutsopoulou S, et al. ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat Immunol 2006 7:606 615.
168. Sato S, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005 6:1087 1095.
169. Chin AI, Shu J, Shi CS, Yao Z, Kehrl JH, Cheng G. TANK potentiates TRAF-mediated JNKSAPK activation through the GCK pathway. Mol Cell Biol 1999 19:6665 6672.
170. Schneider F, et al. The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. PLoS Biol 2008 6:86 98.
171. Gruss H-J, et al. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994 84:2305 2314.
172. Carbone A, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995 85:780 789.
173. Tong AW, Stone MJ. CD40 and the effect of anti-CD40 binding on human multiple myeloma clonogenicity. Leuk Lymphoma 1996 21:1 8.
174. Urashima M, et al. CD40L triggers IL-6 mediated B cell differentiation. Leuk Res 1996 20:507 515.
175. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered IL-6 secretion in multiple myeloma. Blood 1995 85:1903 1912.
176. Planken EV, Dijkstra NH, Bakkus M, Willemze R, Kluin-Nelemans JC. Proliferation of precursor B-lineage ACLL by activating the CD40 antigen. Brit J Hematol 1996 95:319 326.
177. Renard N, et al. Demonstration of functional CD40 in B-lineage ALL cells in response to T-cell CD40L. Blood 1996 87:5162 5170.
178. Greiner A, et al. Low-grade B cell lymphomas of MALT require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am J Pathol 1997 150:1583 1593.
179. Pham LV, et al. A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-kB and autonomous cell growth in B cell lymphomas. Immunity 2002 16:37 50.
180. Zhou H-J, et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood 2007 110:2121 2127.
181. Ghia P, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998 91:244 251.
182. L. J Immunol 2008 181:1001 1011.
183. Henriquez NV, Floettmann E, Salmon M, Rowe M, Rickinson AB. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to EBV LMP1. J Immunol 1999 162:3298 3307.
184. van den Oord J, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1997 149:1953 1961.
185. Bartrla R, Linnebacher M, Rudy W, Stumm S, Wallwiener D, Gückel B. CD40-expressing carcinoma cells induce down-regulation of CD154 and impair T cell functions. Cancer Res 2002 62:2052 2057.
186. - inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 2007 204:1267 1272.
187. Funakoshi S, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994 83:2787 2794.
188. Eliopoulos AG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the TNF superfamily. Mol Cell Biol 2000 20:5503 5515.
189. Dicker F, Kater AP, Fukuda T, Kipps TJ. FasL (CD178) and TRAIL synergistically induce apoptosis of CD40-activated CLL B cells. Blood 2005 105:3193 3198.
190. Law C-L, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. In:Grewal IS ed. Therapeutic Targets of the TNF Superfamily: Landes Bioscience, Austin, TX. 2009:8 36.
191. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1990 56:1909 1916.
192. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J, Trejdosiewicz LK. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNKAP-1 activation. Cell Death Diff 2006 1:1 13.
193. Elmetwali T, Young LS, Palmer DH. CD40L-induced carcinoma cell death: a balance between activation of TRAF3-dependent death signals and suppression of TRAF6-dependent survival signals. J Immunol 2010 184:1111 1120.
194. Schultze JL, Grabbe S, von Bergwelt-Baildon MS. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 2004 25:659 664.
195. Hill SC, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005 174:41 50.
196. Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C, Servet-Delprat C. Cytotoxic activity of human DC is differentially regulated by dsRNA and CD40 ligand. J Immunol 2001 167:3765 3772.
197. Broomfield SA, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009 182:5217 5224.
198. Pope JH, Horne MK, Scott W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 1968 3:857 866.
199. Hammerschmidt W, Sugden B. Genetic analysis of immortalizing functions of EBV in human B lymphocytes. Nature 1989 340:393 397.
200. Baichwal VR, Sugden B. Transformation of Balb 3T3 cells by the BNLF-1 gene of EBV. Oncogene 1988 2:461 467.
201. Moorthy RK, Thorley-Lawson DA. All three domains of the EBV-encoded LMP-1 are required for transformation of Rat-1 fibroblasts. J Virol 1993 67:1638 1646.
202. Masy E, et al. Human monocytic cell lines transformed in vitro by EBV display a type II latency and LMP1-dependent proliferation. J Virol 2002 76:6460 6472.
203. Eliopoulos AG, et al. EBV-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kB pathway involving TRAFs. Oncogene 1997 14:2899 2916.
204. Fahraeus R, et al. Expression of EBV-encoded proteins in naspharyngeal carcinoma. Int J Cancer 1988 42:229 238.
205. Nicholson LJ, et al. EBV LMP1 does not inhibit differentiation and induces tumorigenicity of human epithelial cells. Oncogene 1997 15:275 283.
206. Deyrup AT. EBV-associated epithelial and mesenchymal neoplasms. Human Pathol 2008 39:473 483.
207. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The EBV LMP1 induces IL-10 production in Burkitt lymphoma lines. Int J Cancer 1994 57:240 244.
208. Oudejeans JJ, Jiwa NM, Meijer CJLM. EBV in Hodgkin's disease: more than just an innocent bystander. J Pathol 1997 181:353 356.
209. Herbst H, Samol J, Foss H, Raff T, Niedobitek G. Modulation of IL-6 expression in Hodgkin and Reed-Sternberg cells by EBV. J Pathol 1997 182:299 306.
210. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004 104:3009 3020.
211. Dutton A, et al. Bmi-1 is induced by the EBV oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 2007 109:2597 2603.
212. Lyons SF, Liebowitz DN. The roles of human viruses in the pathogenesis of lymphoma. Sem Oncol 1998 25:461 475.
213. Liebowitz D. EBV and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Eng J Med 1998 338:1413 1421.
214. O'Grady JT, Stewart S, Lowrey J, Howie SEM, Krajewski AS. CD40 expression in Hodgkin's disease. Am J Pathol 1994 144:21 26.
215. Zimber-Strobl U, et al. EBV LMP1 is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J 1996 15:7070 7078.
216. Murphy WJ, et al. Antibodies to CD40 prevent EBV-mediated human B-cell lymphomagenesis in SCID mice given human peripheral blood lymphocytes. Blood 1995 86:1946 1953.
217. Stunz L, Bishop G. In vivo interactions between CD40 and LMP1. FASEB J 2005 19:A347 A348.
218. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Sem Immunol 2009 21:293 300.
219. Durie FH, Fava RA, Foy TM, Aruffo AA, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993 261:1328 1330.
220. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995 154:1470 1480.
221. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40L by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996 97:2063 2073.
222. Early G, Zhao W, Burns C. Anti-CD40L antibody treatment prevents the development of lupus-like nephritis in a subset of NZBxNZW mice. J Immunol 1996 157:3159 3164.
223. Gerritse K, et al. CD40-CD40L interactions in EAE and MS. Proc Natl Acad Sci USA 1996 93:2499 2504.
224. Grewal IS, et al. Requirement for CD40L in costimulation induction, T cell activation, and EAE. Science 1996 273:1864 1867.
225. Paterson RLK, et al. Triggering through CD40 promotes IL-4-induced CD23 production and enhanced soluble CD23 release in atopic disease. Eur J Immunol 1996 26:1979 1984.
226. Balasa B, et al. CD40L-CD40 interactions are necessary for the initiation of insulitis and diabetes in NOD mice. J Immunol 1997 159:4620 4627.
227. Faure GC, Bensoussan-Lejzerowicz D, Bene MC, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. Clin Immunol Immunopathol 1997 84:212 215.
228. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of EBV infection in young patients suggests a possible etiology for SLE. J Clin Invest 1997 100:3019 3026.
229. James JA, et al. SLE in adults is associated with previous EBV exposure. Arth Rheum 2001 44:1122 1126.
230. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, Ashkenazi A. SLE associated with EBV infection. Amer J Kidney Dis 1998 32:825 828.
231. Kang I, et al. Defective control of latent EBV infection in SLE. J Immunol 2004 172:1287 1294.
232. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA. EBV and SLE: a new perspective. J Immunol 2005 174:6599 6607.
233. Takei M, et al. Detection of EBV-encoded small RNA 1 and LMP1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol 1997 9:739 743.
234. Yang L, et al. RF induce signaling from B cells, leading to EBV and B cell activation. J Virol 2004 78:9918 9923.
235. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded LMP1 cooperates with BAFFBLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003 171:5215 5224.
236. Callan MF. EBV, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 2004 16:399 405.
237. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003 24:584 588.
238. Chaganti S, et al. EBV infection in vitro can rescue GC B cells with inactivated Ig genes. Blood 2005 106:4249 4252.
239. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of "crippled" GC B cells from apoptosis by EBV. Blood 2005 106:4339 4344.